Adamas announced the availability of Gocovri (amantadine) extended-release capsules for the treatment of dyskinesia in patients with Parkinson disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. 

Gocovri was approved by the Food and Drug Administration (FDA) in August 2017 as the first drug for this indication. The exact mechanism by which Gocovri exerts its effects in the treatment of dyskinesia in Parkinson disease patients is unknown.

If needed, Gocovri capsules may be administered by opening and sprinkling the entire contents on a teaspoonful of soft food (eg, applesauce). Treatment with Gocovri is contraindicated in patients with end stage renal disease (creatinine clearance <15mL/min/1.73m2). 

Continue Reading

Gocovri is available as 68.5mg and 137mg strength extended-release capsules in 60-count bottles.

Related Articles


Adamas announces US commerical launch of GOCOVRI™ the first and only FDA-approved medication for the treatment of dyskinesia in Parkinson’s disease patients [press release]. Emeryville, CA: Adamas. Published January 8, 2018. Accessed January 10, 2018.

This article originally appeared on MPR